Biocryst Pharmaceuticals Inc (BCRX) concluded trading on Thursday at a closing price of $7.84, with 2.77 million shares of worth about $21.71 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 21.74% during that period and on December 05, 2024 the price saw a gain of about 6.96%. Currently the company’s common shares owned by public are about 207.12M shares, out of which, 189.00M shares are available for trading.
Stock saw a price change of 4.53% in past 5 days and over the past one month there was a price change of 11.13%. Year-to-date (YTD), BCRX shares are showing a performance of 30.88% which increased to 27.90% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.03 but also hit the highest price of $8.88 during that period. The average intraday trading volume for Biocryst Pharmaceuticals Inc shares is 1.93 million. The stock is currently trading 4.71% above its 20-day simple moving average (SMA20), while that difference is up 3.37% for SMA50 and it goes to 17.94% higher than SMA200.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) currently have 207.12M outstanding shares and institutions hold larger chunk of about 78.74% of that.
The stock has a current market capitalization of $1.62B and its 3Y-monthly beta is at 1.77. It has posted earnings per share of -$0.61 in the same period. It has Quick Ratio of 2.73. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BCRX, volatility over the week remained 4.98% while standing at 5.22% over the month.
Stock’s fiscal year EPS is expected to rise by 68.26% while it is estimated to increase by 76.21% in next year. EPS is likely to grow at an annualized rate of 44.80% for next 5-years, compared to annual growth of -3.73% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on November 20, 2023 offering an Overweight rating for the stock and assigned a target price of $10 to it. Coverage by RBC Capital Mkts stated Biocryst Pharmaceuticals Inc (BCRX) stock as an Outperform in their note to investors on September 18, 2023, suggesting a price target of $10 for the stock. On August 04, 2023, Jefferies Upgrade their recommendations, while on July 13, 2023, BofA Securities Upgrade their ratings for the stock with a price target of $10. Stock get a Buy rating from Needham on February 22, 2023.
